(AZN) AstraZeneca PLC BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AZN) AstraZeneca PLC Complete Analysis Pack
Unlock Strategic Clarity
This AstraZeneca PLC BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already includes a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Tagrisso >$5B EGFR NSCLC
Tagrisso is AstraZeneca PLC’s top oncology brand and a global standard for EGFR-mutated non-small cell lung cancer. It posted $6.6 billion in 2024 sales, and its move from metastatic use into earlier-stage disease has widened the addressable market. That mix of strong revenue and label expansion fits a Star in the BCG Matrix.
Farxiga >$7B CKD HF T2D
Farxiga is AstraZeneca PLC’s $7.7B franchise, with 2024 sales above the $7B mark, so it is one of the company’s biggest cash drivers.
Its use spans type 2 diabetes, heart failure and chronic kidney disease, and the SGLT2 class keeps adding new patient groups as evidence builds.
High demand, broad label use and a leading market position make Farxiga a clear Star in AstraZeneca PLC’s BCG Matrix.
Imfinzi >$4B immuno-oncology
Imfinzi stayed a Star for AstraZeneca PLC, with annual sales above $4B as it expanded across lung and bladder cancer. The franchise now spans multiple settings, including earlier-stage and combo use, which keeps demand rising in a large immuno-oncology market. That breadth supports continued growth, not just a one-off launch.
Enhertu >$3B HER2 cancers
Enhertu has crossed the $3 billion sales mark and remains one of AstraZeneca PLC's fastest-growing oncology assets through the Daiichi Sankyo deal. Its use in HER2-positive breast and lung cancer keeps expanding, which signals strong share gains in a large, high-value market.
The drug's rapid uptake supports Star status in the BCG Matrix because it combines high growth with rising commercial scale. In 2025, the HER2 segment stayed one of the most important growth pools in oncology, and Enhertu kept taking share in both second-line and earlier settings.
- Annual sales already above $3 billion
- Growing in breast and lung cancer
- Backed by AstraZeneca and Daiichi Sankyo
Calquence >$2B BTK hematology
Calquence stayed a Star for AstraZeneca PLC, with 2025 sales above $2 billion and strong demand in chronic lymphocytic leukemia and related B-cell cancers.
It is gaining physician adoption in a large hematology market, and AstraZeneca PLC keeps investing in trials and promotion to defend share.
That mix of high growth, scale, and continued spend fits the Star bucket in the BCG Matrix.
- 2025 sales: above $2 billion
- Core use: CLL and related indications
- Strong adoption supports growth
AstraZeneca’s Star Drugs Are Driving Growth
Stars in AstraZeneca PLC’s BCG Matrix are Tagrisso, Farxiga, Imfinzi, Enhertu, and Calquence. In 2025, Farxiga topped $7B, Tagrisso was $6.6B in 2024, Imfinzi was above $4B, Enhertu passed $3B, and Calquence was above $2B. Their mix of high sales and strong growth keeps them in the Star bucket.
| Drug | 2025/2024 sales | Star signal |
|---|---|---|
| Farxiga | $7.7B | Broad use, still growing |
| Imfinzi | >$4B | Expanding oncology labels |
| Enhertu | >$3B | Fast share gains |
| Calquence | >$2B | Rising hematology use |
What is included in the product
Detailed Word Document
AstraZeneca PLC BCG Matrix: identifies Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page AstraZeneca PLC BCG Matrix highlighting each quadrant for quick, C-level decision-making
Reference Sources
Provides a clear source trail for AstraZeneca PLC, boosting credibility and helping decision-makers verify key assumptions fast.
Cash Cows
Symbicort legacy inhaler
Symbicort is a mature respiratory brand with long global use and low market growth. It now faces heavy generic competition, so its growth has slowed, but it still throws off steady cash for AstraZeneca PLC. That mix of weak growth and ongoing cash generation makes Symbicort a classic Cash Cow.
Soliris orphan complement
Soliris, approved in 2007, is AstraZeneca PLC's classic rare-disease cash cow: a mature C5 inhibitor with a large, sticky patient base in PNH and aHUS. Even with Ultomiris and biosimilar pressure, it still throws off meaningful cash from a franchise that has been built over 18 years. Its role is now harvest, not growth.
Lynparza >$2B PARP leader
Lynparza remains AstraZeneca PLC’s PARP leader, with 2024 sales of $2.9bn and a broad global oncology footprint. The category is more mature than newer launches, but Lynparza still holds the leading share in a large, repeat-use cancer franchise. That mix of scale, reach, and cash generation makes it a clear Cash Cow.
Brilinta >$1B antiplatelet
Brilinta is a mature antiplatelet brand in a slow-growing cardiovascular market. AstraZeneca said it has topped $1bn in annual sales, but US generic pressure has already cut growth, so the drug still adds cash even as the franchise ages.
- Mature brand
- Low-growth category
- Still cash generative
- Facing generic erosion
This makes Brilinta a clear Cash Cow in AstraZeneca PLC's BCG matrix: it supports earnings and funding, but no longer drives major growth.
Fasenra >$1B severe asthma
Fasenra is a mature Cash Cow for AstraZeneca PLC, with annual sales above $1B and a defined base in severe eosinophilic asthma. It serves a chronic, specialist-treated population, so revenue is steadier than newer launches, even if growth has slowed versus AstraZeneca PLC’s newer immunology and oncology drugs.
Its established brand, repeat dosing, and broad payer access support durable cash flow. In BCG terms, Fasenra fits a Cash Cow because it still throws off strong revenue from a well-known respiratory franchise, but it no longer needs the same growth spend as AstraZeneca PLC’s faster-rising assets.
- Annual sales stay above $1B
- Stable, defined asthma patient base
- Slower growth, strong cash generation
AstraZeneca’s Cash Cows Still Fund Growth, But Erosion Is Creeping In
AstraZeneca PLC’s Cash Cows are mature brands with slow growth but strong cash flow: Symbicort, Soliris, Lynparza, Brilinta, and Fasenra. Lynparza posted $2.9bn in 2024 sales, and Fasenra stayed above $1bn, while Brilinta and Symbicort face generic erosion. These drugs still fund the portfolio, but growth is limited.
| Brand | Signal | 2024 sales |
|---|---|---|
| Lynparza | Leader | $2.9bn |
| Fasenra | Cash flow | >$1bn |
| Brilinta | Generic pressure | $1bn+ |
Preview the Actual Deliverable
AstraZeneca PLC Reference Sources
The AstraZeneca PLC BCG Matrix preview you see is the exact same document you’ll receive after purchase. There are no demo pages or hidden changes—just the full, ready-to-use report. Once purchased, the file is instantly available for download and use. What you preview here is what you get.
Dogs
Vaxzevria COVID-19 vaccine
Vaxzevria is no longer a growth engine for AstraZeneca PLC. COVID-19 vaccine demand has fallen far below the 2021 peak, and AstraZeneca no longer reports Vaxzevria as a material revenue driver. With weak demand and a small market share, it fits the Dog quadrant in the BCG Matrix.
Crestor generic statin
Crestor, AstraZeneca PLC’s rosuvastatin brand, is a mature statin with little remaining exclusivity value. Generic competition has pushed prices down hard and cut share; in the U.S., rosuvastatin is now sold mainly as low-cost generics, with AstraZeneca’s branded sales only a small residual line item. It fits the Dogs box: low growth, low share, and weak cash upside.
Seroquel generic antipsychotic
Seroquel (quetiapine) is a legacy AstraZeneca PLC psychiatric brand that has faced heavy generic erosion after patent expiry, so branded sales have been in long-term decline. The antipsychotic market is mature, and the franchise has little remaining growth headroom as low-cost generics dominate prescriptions. In BCG terms, that puts Seroquel in the Dog bucket: low growth, weak competitive position, and limited capital appeal.
Nexium generic PPI
Nexium (esomeprazole) is now an off-patent PPI in a mature acid-suppression market, so branded pricing power is weak and low-cost generics dominate. Its US exclusivity ended in 2014, and the class is crowded with cheap omeprazole and pantoprazole options, so AstraZeneca PLC gets little strategic lift from the brand. That makes Nexium a clear Dog in the BCG Matrix.
- Off-patent and commoditized
- Weak branded share
- Low growth, low margin
Arimidex generic aromatase inhibitor
Arimidex, AstraZeneca PLC’s anastrozole brand, is now a mature breast-cancer drug with little growth left; AstraZeneca’s 2025 reporting no longer treats it as a material driver, while generic anastrozole dominates on price. The key patent expired years ago, so substitution has steadily eroded branded demand. That is classic low-growth, low-share Dog territory in the BCG Matrix.
- Older brand, weak growth
- Patent loss cut pricing power
- Generic anastrozole now leads
- Fits Dogs in BCG
AstraZeneca’s Aging Brands Face Generic Pressure
These AstraZeneca PLC brands are Dogs because they are mature, off-patent, and face generic-led pricing pressure. Vaxzevria, Crestor, Seroquel, Nexium, and Arimidex now add little growth and have weak share in low-growth markets.
| Brand | Dog signal |
|---|---|
| Vaxzevria | Demand collapse |
| Crestor | Generic erosion |
| Seroquel | Patent loss |
| Nexium | Off-patent |
| Arimidex | Weak growth |
Question Marks
Tezspire severe asthma
Tezspire is in a fast-growing severe-asthma space, where biologic sales are already in the $10bn-plus range and rivals like Dupixent, Nucala, Fasenra, and Xolair have bigger franchises. AstraZeneca is still building share, even as Tezspire's 2024 sales topped $1bn, so the asset has clear growth upside but limited scale versus leaders. That mix of high market growth and lower market share makes Tezspire a Question Mark in AstraZeneca PLC's BCG Matrix.
Saphnelo lupus
Saphnelo is a Question Mark in AstraZeneca PLC’s BCG Matrix: it targets systemic lupus erythematosus, a disease affecting about 3.4 million people worldwide, with clear unmet need. Uptake is still early versus AstraZeneca PLC’s larger immunology brands, so revenue share remains modest. The drug has real growth potential, but its market position is not yet proven.
Truqap breast cancer
Truqap (capivasertib) is a newer breast-cancer launch for AstraZeneca PLC in a huge oncology market, but it is still early in uptake, so it fits a Question Mark. In CAPItello-291, Truqap plus fulvestrant cut disease progression or death risk by 40% overall and by 50% in PIK3CA/AKT1/PTEN-altered tumors, which supports growth. It still needs fast share gains against entrenched CDK4/6 and PI3K rivals to move toward Star status.
Wainzua ATTR-PN
Wainua is AstraZeneca PLC’s eplontersen for hereditary transthyretin amyloidosis with polyneuropathy, a rare, high-value niche that still had only about 5,000 diagnosed patients in the U.S. in 2025. The ATTR-PN market is expanding fast as diagnosis improves, but AstraZeneca’s share is still early, so Wainua fits a Question Mark in the BCG Matrix.
In 2025, AstraZeneca and Ionis were still building uptake after the U.S. launch, while rivals in ATTR therapy had already reached much larger installed bases, so Wainua needs heavy promotion and access wins to convert growth into share.
- Rare disease, high price, high growth.
- Low current share, still scaling.
- Needs proof to become a Star.
Voydeya PNH
Voydeya (danicopan) targets complement-mediated disease in paroxysmal nocturnal hemoglobinuria, a niche but high-value rare-disease market. AstraZeneca PLC’s brand is still early in commercialization, so current share is low even as adoption can grow fast if add-on use to C5 therapy expands. That mix of small base and clear upside fits a Question Mark in the BCG Matrix.
- Rare-disease niche
- Early sales ramp
- Low share, high upside
AstraZeneca’s Question Marks: Big Potential, Small 2025 Sales
Tezspire, Saphnelo, Truqap, Wainua, and Voydeya are AstraZeneca PLC Question Marks: each sits in a growing, high-value market, but 2025 sales and share are still small versus bigger rivals. Tezspire passed $1bn in 2024 sales, yet Dupixent and other biologics still lead. Truqap, Wainua, and Voydeya are still early launches, so they need faster uptake to turn growth into scale.
| Asset | 2025/2026 signal | BCG fit |
|---|---|---|
| Tezspire | $1bn+ 2024 sales | Question Mark |
| Saphnelo | Early lupus uptake | Question Mark |
| Truqap | Early breast-cancer ramp | Question Mark |
| Wainua | ~5,000 U.S. diagnosed patients | Question Mark |
| Voydeya | Early PNH launch | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.